Bob T. Li, MD, PhD, MPH, FRACP, is Senior Fellow on Global Public Health at the Asia Society Policy Institute’s Center for China Analysis. Dr. Li is an Australian medical oncologist, physician-scientist and SVP Global Head of Medical Affairs, Oncology at AstraZeneca. He previously served as Vice President, Global Research Affairs, and Physician Ambassador to China and Asia-Pacific at Memorial Sloan Kettering Cancer Center, New York. He was also tenure-track associate professor at Weill Cornell Medicine, Cornell University.

Dr. Li is internationally renowned for his expertise in precision oncology, cancer drug development, and clinical trials regulatory policy harmonization. Dr. Li was the international principal investigator of multiple pivotal clinical trials of precision medicines including “drugging the undruggable” KRAS, and targeting HER2 across multiple cancer types. These international trials have resulted in historic FDA approvals of novel precision medicines and transformed practice guidelines for patients with lung cancers worldwide. Dr. Li has received numerous awards for his practice changing research, including the competitive NIH R01 grant and has published over 100 original articles in prestigious scientific journals including first and senior author manuscripts in the New England Journal of Medicine, Nature, Nature Medicine, Lancet Oncology, Cancer Discovery, and Journal of Clinical Oncology.

He is Co-Founder of the multi-stakeholder platforms Bloomberg New Economy International Cancer Coalition and Cure4Cancer, and his work on patient-centric international clinical trials as part of a growing global movement is frequently featured on Forbes.com. Dr. Li’s international leadership at the U.S.-Australia Cancer Alliance is recognized by the U.S. and Australian governments, and his global policy harmonization efforts including a partnership with the FDA’s Project Orbis are recognized by public and private sector leaders in the U.S. and China. Through advancing global health equity and patient-centric care by leveraging collaboration and technology, his career is dedicated to bringing the world together to accelerate the cure for cancer in this lifetime.